Therapeutic Programs

therapeutic programs

Next Generation Targets

scientistArvinas is pioneering the development of novel protein degraders known as PROTACs, or proteolysis-targeted chimeras. We have been successful in degrading over 85% of proteins tested, and are engineering new PROTACs to degrade protein targets in and outside of oncology as well as those proteins that are considered “undruggable” by traditional small molecule inhibitors. These PROTACs will become the pipeline of the future for Arvinas.